The aetiology of sporadic medullary thyroid carcinoma is unknown. About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C4T; S836S) occurred at a signi®cantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P=0.03). Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P=0.01). These ®ndings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.
The aetiology of sporadic medullary thyroid carcinoma is unknown. About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C4T; S836S) occurred at a signi®cantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P=0.03). Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P=0.01). These ®ndings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.
Keywords: tyrosine kinase; polymorphism; germline mutation; somatic mutation; medullary thyroid cancer Medullary thyroid carcinoma (MTC) comprises approximately 5 ± 10% of all thyroid malignancies (Bergholm et al., 1990) . About 75% of all MTCs are believed to be sporadic (Bergholm et al., 1990; Raue et al., 1993) , and the remaining 25% comprise the autosomal dominant multiple endocrine neoplasia type 2 (MEN 2) syndromes, MEN 2A, MEN 2B and familial MTC (Farndon et al., 1986; Schimke, 1984) . Germline mutations of the RET protooncogene aecting exons 10, 11, 13, 14, 15 and 16 have been found to be associated with MEN 2 (Bolino et al., 1995; Carlson et al., 1994; Donis-Keller et al., 1993; Eng et al., 1994 Eng et al., , 1995 Farndon et al., 1986; Gimm et al., 1997; Hofstra et al., 1994; Mulligan et al., 1993; Schimke, 1984; Smith et al., 1997) . Speci®cally, germline mutation at codon 918 (M918T) in exon 16 is associated with 495% of MEN 2B , which is characterized by a more severe form of MTC and phaeochromocytoma occurring at a young age and classic stigmata such as ganglioneuromatosis and a marfanoid habitus. Functional, biochemical and limited animal modelling studies have demonstrated that the RET mutations which characterize MEN 2 are capable of activation, sometimes in a constitutive manner, of the RET signalling pathway (Borrello et al., 1995; Ceccherini et al., 1997; Michiels et al., 1997; Pasini et al., 1997; Santoro et al., 1995) . The MEN 2B-type mutation, M918T, has been shown to alter substrate speci®city (Borrello et al., 1995; Santoro et al., 1995; Songyang et al., 1995) . Interestingly, a median of 50% of sporadic MTC harbour somatic M918T mutations . Despite our rapidly accumulating knowledge of the genetics and biochemistry of RET, it is not really known how M918T occurs. Further, while a number of the MEN 2-and MTC-associated RET mutations have been shown to be functionally signi®cant, it is not known whether neutral sequence variants play other interacting, predisposing or modifying roles in the pathogenesis of MEN 2 or sporadic MEN 2-related tumours.
In this study, we analysed paired somatic and germline DNA from 50 sporadic MTC cases (German origin 38, US origin 12) to determine the frequency of somatic M918T and the frequency of other RET sequence variants in the germline of individuals versus race-matched, region-matched control individuals. Patients were classi®ed as having sporadic MTC when no MEN 2-speci®c germline RET mutations could be identi®ed. Clinically, none of the cases had family histories of MTC, phaeochromocytoma or parathyroid disease.
MTC tumour specimens were obtained from each of 36 patients and¯ash frozen in liquid nitrogen. In the remaining 14 patients, MTC samples were paranembedded. All samples were obtained with informed consent. Blood and tumour DNA were extracted using the QIAamp tissue kit according to the manufacturer's instructions (Qiagen, Santa Clarita, CA, USA).
To screen for the presence of somatic M918T in each of these tumours, exon 16 amplicons were prepared using either fRET16 and rRET16 or CRT5H and CRT5G and PCR conditions as previously described. An additional second-round PCR using identical conditions was performed using primers designed to introduce a RsaI restriction site in the presence of the codon M918T mutation . Overnight digestion of the f16Rsa-generated exon 16 amplicon was then performed with an excess of the restriction endonuclease RsaI (New England Biolabs, Inc., Beverly, MA, USA). Additionally, overnight digestion of the f16Rsa-generated PCR product was also performed with an excess of the restriction endonuclease Sau3AI as a control for digestion. Of 50 sporadic MTCs, 25 (50%) were found to have somatic M918T, a frequency similar to that reported in the literature . M918T was shown to be absent in the corresponding germline DNA. Semi-automated sequence analysis (Liaw et al., 1997) In an attempt to search for additional somatic mutations in these MTC, PCR amplicons of exons 13 ± 15 were subjected to direct sequencing. We did detect a somatic 12-bp deletion in exon 15, which was absent in the germline. This novel mutation, c.2622/3/4/5-2633/4/ 5/6del12 (because of repetitive sequences, it was impossible to determine which of four possible combinations of 12 nucleotides had been deleted) results in a 4-amino acid in-frame deletion (RDVYEE to RE).
We next turned our attention to examining the frequency of seven known RET sequence variants/ polymorphisms in the germline of the 50 sporadic MTC patients and comparing them to that in race-and region-matched normal controls. The frequencies of both alleles at six of the seven polymorphic sites were similar in cases and controls (Table 1) . Of interest, we found an over-representation of a rare sequence variant, c.2439C4T/S836S (exon 14), in the germline of patients with sporadic MTC (Table 1) . In one case, neither sequence analysis nor restriction analysis could clearly delineate the presence or absence of the c.2439C4T sequence variant in the germline despite multiple repetitions. Therefore, this case was excluded for the purpose of statistical analyses. Of 49 evaluable patients, nine had the heterozygous germline sequence variant c.2439C4T (9%, i.e. 9T:89C). Analysis of 140 chromosomes from 70 race-matched, region-matched control patients (German origin 50, US origin 20) demonstrated the presence of the T sequence variant in 5 (3.6%) alleles (data not shown). The 3.6% allele frequency in our controls is similar to the 3.7% in 188 French alleles reported in the literature (Rodien et al., 1997) . Therefore, the 9% T allele frequency in our cohort of MTC patients is signi®cantly higher than that occurring in controls without MTC (Fisher's exact test, P=0.03). Further, eight of those nine patients who carried the rare sequence variant at codon 836 (c.2439C4T) also had tumours with somatic M918T mutation (c.2684T4C). The association of the c.2439C4T sequence variant and the presence of somatic M918T in corresponding tumours is also statistically signi®cant (Table 2, Fisher's exact test, P=0.01).
To determine whether the c.2439T variant lies on the same allele as the M918T mutation, we used genomic DNA extracted from seven¯ash frozen tumours and Allele 1 is always de®ned as the one with the restriction site absent.
c PCR conditions and primers have been previously described , except for primers used to amplify exon 3: f3-Sau3AI (5'-CTTTCCCCTGCTCACCGTCTACCTCAAGAT-3'), and exon 7: RET-7R (5'-TTGTACTGGACGTTGATGCC-3') RET polymorphisms in medullary thyroid carcinoma O Gimm et al performed long distance PCR encompassing RET exons 14, 15 and 16. This analysis could not be done in the remaining two tumours because they were paran-embedded and a fragment of about 2.5 kb could not be ampli®ed. Long distance PCR was performed using 100 ± 200 ng of genomic DNA template, 0.4 mM of primer CRT4N, 0.4 mM of primer M918T-R (5'-AAAAGGGATTCAATTGCCG-3'), and the TaKaRa LA PCR Kit Ver 2 (TaKaRa Shuzo Co., Ltd., Japan): 16 PCR buer, 8 ml of dNTP, and 0.5 ml LA Taq in a ®nal volume of 50 ml. The PCR was hot started at 948C for 2 min, after which the LA Taq was added, followed by 30 cycles of 20 s at 988C, 30 s at 628C, and 15 min at 688C, and a ®nal extension of 10 min at 728C. The forward primer CRT4N was positioned in intron 13 upstream of codon 836. The novel M918T-R primer was designed such that it would anneal to the template only in the presence of the M918T (c.2684T4C) mutation. Under these PCR conditions, therefore, the primer M918T-R was shown to amplify only the allele carrying the mutation M918T (c.2684T4C). This was a method for selecting for only the allele bearing M918T (Figures 1 and 2a) . Sequence analysis of this long distance amplicon con®rmed the homogenous presence of only the M918T (ACG) allele in all instances (data not shown). Using this allelespeci®c PCR product as template, a second round PCR was performed using the exon 14-speci®c primers CRT4N and CRT4K. This exon 14 amplicon was subjected to AluI digestion. In the presence of the c.2439C wildtype sequence, AluI would digest the amplicon. In contrast, in the presence of the variant (c.2439T) allele, AluI would not digest the amplicon. Of the 7 M918T-speci®c exon 14 amplicons generated, ®ve were not digested by this enzyme and thus contained the c.2439T variant, while two were completely digested and thus, was shown to contain the c.2439C wildtype sequence (Figure 2a ). In summary, the c.2439C4T variant was on the same allele as the M918T mutation in ®ve MTCs while in the remaining two cases, the T variant and the M918T mutation were on opposite alleles. In sum, only the c.2439C4T variant appeared to be over-represented in sporadic MTC cases compared to geographic controls. More interestingly, eight of the nine patients with the C/T variant also had somatic M918T. This variant at codon 836 has been described in the literature with a frequency of 3.7% (Rodien et al., 1997) , which is very similar to the frequency of 3.6% which we found among our 140 control alleles. One could argue that the higher incidence of this sequence variant in patients with MTC in our study is an artefact secondary to small sample size. However, the frequencies of all other sequence polymorphisms noted in our series of MTC patients were similar to those previously reported by others . These observations argue strongly against the S836S-M918T association as coincidence due to small sample size and suggest that the association of the germline c.2439C4T variant is somehow related to somatic M918T and the pathogenesis of a subset of sporadic MTC. If the germline c.2439C4T variant is associated with the development of MTC, i.e., a low penetrance allele, then, it may be postulated, without experimental evidence thus far, that some instances of FMTC', especially families which comprise only two aected cases, might be due to the presence of this low penetrance allele and not the classic FMTC mutations. If this was true, such`small' FMTC families should have germline S836S, no typical MEN 2 type mutation, and the MTC tumour should have somatic M918T. Anecdotally, one FMTC family with no classic MEN 2-type RET mutations had the germline c.2439C4T variant which appeared to segregate with disease (Gimm and Eng, unpublished observations). Obviously, a concerted eort, perhaps by the Interna- Figure 1 Algorithm to determine whether the S836S T variant lies on the same allele as the M918T (ACG) mutation tional RET Mutation Consortium would be needed to prove this postulate with adequate statistical power.
The precise mechanism by which c.2439T and M918T may interact in sporadic MTC genesis is unknown and open to speculation. Since this sequence variant does not lead to an amino acid alteration, S836S, it is dicult to imagine how this conserved polymorphism may aect RET. However, it is conceivable that the sequence variant c.2439T enhances the expression of RET. In this regard, it has been shown that polymorphic sequence variants can lead to production of dierent amounts of mRNA (Leviev et al., 1997) . At the nucleotide level, several possibilities exist. One might hypothesize that the AGC4AGT polymorphism causes the creation of a cryptic splice donor, splice acceptor or splice enhancer, therefore, leading to an altered protein. There is precedent in this regard. For example, alternative splicing of the human growth hormone transcript might be the result of an unusual polymorphism (Stallings-Mann et al., 1996) . Dierential splicing of episialin mRNA has been shown to be dictated by a single exonic nucleotide polymorphism (Ligtenberg et al., 1991) . Further data demonstrate that a splice siteassociated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas (Platten et al., 1997) . Similar mechanisms are conceivable in alternative splicing of RET mRNA. Unfortunately, cDNA was not available in our patients and this postulate remains speculative.
The observation of the germline c.2439T variant in both cis and trans with the somatic M918T mutation must also be explained. In ®ve patients, it appears that the somatic M918T mutation occurs on the c.2439T allele rather than in the wildtype allele. In this situation, the c.2439T variant may create an unstable sequence downstream at codon 918, resulting in the somatic M918T mutation instead of directly participating in the tumourigenic process. Such a mechanism has been observed in the APC gene in a fraction (28%) of Ashkenazim with familial colorectal cancer where additional somatic mutations were more often found on that allele carrying a seemingly innocuous germline missense mutation predicted to result in a conservative amino acid change (I1307K) (Laken et al., 1997) . Although a plausible explanation when the c.2439T and M918T variants are on the same allele, this mechanism cannot explain the origin of the somatic M918T mutation in trans with the c.2439T variant in the remaining two patients. Finally, the apparent preference of the M918T mutation to occur on the c.2439T allele might be due to the small sample size.
While our data suggest that a neutral germline sequence variance RET may somehow predispose to sporadic MTC, especially those that harbour somatic M918T, it remains for further largescale molecular epidemiologic studies to determine if this is a phenomenon generalizable to dierent populations and for functional analyses to prove that this variant indeed contributes to the MTC phenotype. 
